Bristol Myers Squibb (BMY) Surpasses Market Returns: Some Facts Worth Knowing

Bristol Myers Squibb (BMY) ended the recent trading session at $54.19, demonstrating a +1.61% change from the preceding day's closing price. The stock exceeded the S&P 500, which registered a gain of 0.88% for the day. Elsewhere, the Dow gained 0.38%, while the tech-heavy Nasdaq added 1.31%. Heading into today, shares of the biopharmaceutical company had gained 16.09% over the past month, outpacing the Medical sector's gain of 1.2% and the S&P 500's gain of 2.48%.The investment community will be paying close attention to the earnings performance of Bristol Myers Squibb in its upcoming release. The company is slated to reveal its earnings on February 5, 2026. It is anticipated that the company will report an EPS of $1.71, marking a 2.4% rise compared to the same quarter of the previous year. In the meantime, our current consensus estimate forecasts the revenue to be $12.28 billion, indicating a 0.49% decline compared to the corresponding quarter of the prior year. BMY's full-year Zacks Consensus Estimates are calling for earnings of $6.51 per share and revenue of $47.91 billion. These results would represent year-over-year changes of +466.09% and -0.81%, respectively. It's also important for investors to be aware of any recent modifications to analyst estimates for Bristol Myers Squibb. Such recent modifications usually signify the changing landscape of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the business outlook. Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system. Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has moved 0.08% lower. Bristol Myers Squibb presently features a Zacks Rank of #3 (Hold). From a valuation perspective, Bristol Myers Squibb is currently exchanging hands at a Forward P/E ratio of 8.19. This represents a discount compared to its industry average Forward P/E of 18.4. Also, we should mention that BMY has a PEG ratio of 8.19. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. By the end of yesterday's trading, the Medical - Biomedical and Genetics industry had an average PEG ratio of 1.68. The Medical - Biomedical and Genetics industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 95, positioning it in the top 39% of all 250+ industries. The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions. Zacks' Research Chief Picks Stock Most Likely to "At Least Double"Our experts have revealed their Top 5 recommendations with money-doubling potential – and Director of Research Sheraz Mian believes one is superior to the others. Of course, all our picks aren’t winners but this one could far surpass earlier recommendations like Hims & Hers Health, which shot up +209%.See Our Top Stock to Double (Plus 4 Runners Up) >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Bristol Myers Squibb Company (BMY): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks